舒血宁注射液对急性脑梗死患者血清VEGF,vWF和MMP-9的影响

目的:探讨舒血宁注射液对急性脑梗死患者(ACI)血清血管内皮生长因子(VEGF)、血浆血管性血友病因子(vWF)和基质金属蛋白酶-9(MMP-9)的影响.方法:80例ACI患者随机分为观察组和对照组各40例.两组均采用常规基础治疗,对照组采用依达拉奉30 mg,iv gtt,bid；观察组采用舒血宁注射液25 mg,iv gtt,qd,疗程均为14 d.于治疗1,7,14 d,采用酶联免疫吸附试验测定血清VEGF,vWF,MMP-9水平；并按卒中量表(NIHSS)对神经功能进行评价.结果:治疗后两组NHISS评分均呈下降趋势,14 d观察组NHISS评分低于对照组(P＜0.05)；治疗后观察组神经功能评价优于对照组(P＜0.05)；14d观察组血清VEGF高于对照组(P＜0.05),观察组vWF和MMP-9水平低于对照组(P ＜0.05,P＜0.01).结论:舒血宁注射液能改善ACI患者神经缺损功能,其作用机制可能与其调节VEGF,vWF,MMP-9水平有关.

Effect of Shuxuening Injection on VEGF, vWF and MMP-9 in Patients with Acute Cerebral Infarction

Objective: To observe the effects of Shuxuening injection on serum vascular endothelial growth factor (VEGF), plasma von Willebrand factor (vWF) and matrix metalloproteinase-9 (MMP-9) in patients with acute cerebral infarction (ACI). Method: Eighty subjects with ACI were randomly divided into observation group (n=40) and control group (n=40). Both groups were received conventional treatment. The control group was given edaravone 30 mg ivgtt, bid; the observation group was given Shuxuening injection 25 mL ivgtt. qd, all for 14 days. The level of VEGF, vWF and MMP-9 were observed by enzyme-linked immunosorbent assay (ELISA) and neurologic function was evaluated. Result: The post-treatment NHISS scores of both groups showed a declining curve, the NHISS score of the observation group at 14 day was lower than that in the control group (P<0.05). The post-treatment neurological function evaluation of the observation group was superior to the control group (P<0.05). The level of serum VEGF of the observation group at 14 day was higher than the control group (P<0.05), the level of vWF and MMP-9 in the observation group was lower than those in the control group (P<0.05, P<0.01). Conclusion: Shuxuening injection can improve neurologic impairment of patients with ACI, the mechanism may be related to the levels of VEGF, vWF and MMP-9.